Dosing & Uses
Dosage Forms & Strengths
capsule
- 200mg
Basal Cell Carcinoma
Indicated for adults with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy
200 mg PO qDay
Continue treatment until disease progression or unacceptable toxicity
Dosage Modifications
Renal impairment: No dose adjustment required
Hepatic impairment
- Mild-to-severe (Child-Pugh class A to C): No dosage adjustment required
Interrupt treatment
- Severe or intolerable musculoskeletal adverse reactions
- First occurrence of serum CK elevation between 2.5 and 10x ULN
- Recurrent serum CK elevation between 2.5 and 5x ULN
- Resume dose at 200 mg qDay upon resolution of clinical signs and symptoms
Permanently discontinue
- Serum CK elevation >2.5x ULN with worsening renal function
- Serum CK elevation >10x ULN
- Recurrent serum CK elevation >5x ULN
- Recurrent severe or intolerable musculoskeletal adverse reactions
Dosing Considerations
Before initiation
- Verify the pregnancy status of females of reproductive potential
- Obtain serum CK levels and renal function tests
Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
All grades of severity listed unless otherwise indicated
>10% (All Grades)
Increased serum creatinine (92%)
Increased serum creatine kinase (61%)
Muscle spasms (54%)
Alopecia (53%)
Hyperglycemia (51%)
Dysgeusia (46%)
Increased lipase (43%)
Fatigue (41%)
Nausea (39%)
Diarrhea (32%)
Anemia (32%)
Musculoskeletal pain (32%)
Decreased weight (30%)
Lymphopenia (28%)
Decreased appetite (23%)
Myalgia (19%)
Increased ALT or AST (19%)
Abdominal pain (18%)
Increased amylase (16%)
Headache (15%)
Pain (14%)
Vomiting (11%)
>10% (Grade 3-4)
Increased lipase (13%)
1-10% (All Grades)
Pruritus (10%)
1-10% (Grade 3)
Increased serum creatine kinase (8%)
Hyperglycemia (4%)
Increased ALT/AST (4%)
Muscle spasms (3%)
Decreased weight (3%)
Lymphopenia (3%)
Decreased appetite (1%)
Musculoskeletal pain (1%)
Nausea (1%)
Diarrhea (1%)
Vomiting (1%)
Increased amylase (1%)
Warnings
Black Box Warnings
Based on sonidegib’s mechanism of action, can cause embryo-fetal death or severe birth defects when administered to a pregnant woman
Sonidegib is embryotoxic, fetotoxic, and teratogenic in animals
Verify pregnancy status of females of reproductive potential prior to initiating; advise females of reproductive potential to use effective contraception during treatment and for at least 20 months after the last dose
Advise male patients to use condoms, even after a vasectomy, to avoid potential drug exposure to pregnant partners and female partners of reproductive potential during treatment and for at least 8 months after the last dose
Contraindications
None
Cautions
Can cause embryo-fetal death or severe birth defects when administered to a pregnant woman (see Black Box Warnings and Pregnancy sections)
Advise patients not to donate blood or blood products while taking sonidegib and for at least 20 months after the last dose because their blood or blood products might be given to a female of reproductive potential
Musculoskeletal adverse reactions, which may be accompanied by serum creatine kinase elevations, occur with Hedgehog (Hh) pathway inhibitors
Premature fusion of the epiphyses has been reported in pediatric patients exposed to sonidegib and other Hh pathway inhibitors; cases of progressive of epiphyseal fusion reported in pediatric patients receiving other Hh pathway inhibitors; not indicated for use in pediatric patients
Avoid coadministration with moderate/strong CYP3A inhibitors or inducers
Pregnancy & Lactation
Pregnancy
Based on sonidegib’s mechanism of action, can cause fetal harm when administered to a pregnant woman
There are no available data on the use in pregnant women
In animal reproduction studies, oral administration of sonidegib during organogenesis at doses below the recommended human dose of 200 mg resulted in embryotoxicity, fetotoxicity, and teratogenicity in rabbits (teratogenic effects observed included severe midline defects, missing digits, and other irreversible malformations)
Verify pregnancy status of females of reproductive potential prior to initiating
Advise females of reproductive potential to use effective contraception during treatment and for at least 20 months after the last dose
Do not donate blood for at least 20 months after the last dose
Males
- Unknown if sonidegib is present in semen
- Advise male patients to use condoms, even after a vasectomy, to avoid potential drug exposure to pregnant partners and female partners of reproductive potential during treatment and for at least 8 months after the last dose
- Do not donate semen for at least 8 month or blood for at least 20 months
Lactation
Unknown if distributed in human breast milk
Because of the potential for serious adverse reactions in breastfed infants from sonidegib, advise a nursing woman not to breastfeed during treatment and for 20 months after the last dose
Pregnancy Categories
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Mechanism of Action
Hedgehog (Hh) pathway inhibitor; the Hh signaling pathway is important in embryogenesis, but in adults, it is mostly inactive; signaling is relayed by key proteins, including smoothened (SMO)
Hh ligand-expressing cancerous epithelial cells that are activated by the Hh signaling pathway may cause growth promotion; sonidegib binds to and inhibits SMO, a transmembrane protein involved in Hedgehog signal transduction
Absorption
<10% of oral dose is absorbed
Peak plasma time: 2-4 hr (fasting)
Peak plasma concentration: 1030 ng/mL
Minimum plasma concentration: 890 ng/mL
AUC: 22 mcg·h/mL
Distribution
Protein bound: >97%
Vd (Vss/F): 9,166 L
Metabolism
Primarily metabolized by CYP3A
The main circulating compound was unchanged sonidegib (36% of circulating radioactivity)
Elimination
Half-life: 28 days
Excretion: 70% feces; 30% urine
Administration
Instructions
Swallow capsule on an empty stomach, at least 1 hr before or 2 hr after a meal
If a dose is missed, resume dosing with the next scheduled dose
Storage
Store at controlled room temperature (25°C [77°F]); excursions permitted to 15-30°C (59-86°F)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
